Polanco Patricio M, Ding Ying, Knox Jordan M, Ramalingam Lekshmi, Jones Heather, Hogg Melissa E, Zureikat Amer H, Holtzman Matthew P, Pingpank James, Ahrendt Steven, Zeh Herbert J, Bartlett David L, Choudry Haroon A
Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, USA.
Department of Biostatistics, University of Pittsburgh, Pittsburgh, USA.
Ann Surg Oncol. 2016 Feb;23(2):382-90. doi: 10.1245/s10434-015-4838-z. Epub 2015 Oct 1.
High-grade (HG) mucinous appendiceal neoplasms (MAN) have a worse prognosis than low-grade histology. Our objective was to assess the safety and efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS/HIPEC) in patients with high-grade, high-volume (HG-HV) peritoneal metastases in whom the utility of this aggressive approach is controversial.
Prospectively collected perioperative data were compared between patients with peritoneal metastases from HG-HV MAN, defined as simplified peritoneal cancer index (SPCI) ≥12, and those with high-grade, low-volume (HG-LV; SPCI <12) disease. Kaplan-Meier curves and multivariate Cox regression models identified prognostic factors affecting oncologic outcomes.
Overall, 54 patients with HG-HV and 43 with HG-LV peritoneal metastases underwent CRS/HIPEC. The HG-HV group had longer operative time, increased blood loss/transfusion, and increased intensive care unit length of stay (p < 0.05). Incomplete macroscopic cytoreduction (CC-1/2/3) was higher in the HG-HV group compared with the HG-LV group (68.5 vs. 32.6 %; p = 0.005). Patients with HG-HV disease demonstrated worse survival than those with HG-LV disease (overall survival [OS] 17 vs. 42 m, p = 0.009; time to progression (TTP) 10 vs. 14 m, p = 0.024). However, when complete macroscopic resection (CC-0) was achieved, the OS and progression-free survival of patients with HG-HV disease were comparable with HG-LV disease (OS 56 vs. 52 m, p = 0.728; TTP 20 vs. 19 m, p = 0.393). In a multivariate Cox proportional hazard regression model, CC-0 resection was the only significant predictor of improved survival for patients with HG-HV disease.
Although patients with HG-HV peritoneal metastases from MAN have worse prognosis compared with patients with HG-LV disease, their survival is comparable when complete macroscopic cytoreduction is achieved.
高级别(HG)黏液性阑尾肿瘤(MAN)的预后比低级别组织学类型的更差。我们的目的是评估细胞减灭术联合腹腔热灌注化疗(CRS/HIPEC)对于高级别、高负荷量(HG-HV)腹膜转移患者的安全性和有效性,而这种积极治疗方法的实用性存在争议。
前瞻性收集HG-HV MAN腹膜转移患者(定义为简化腹膜癌指数[SPCI]≥12)与高级别、低负荷量(HG-LV;SPCI<12)疾病患者的围手术期数据并进行比较。Kaplan-Meier曲线和多变量Cox回归模型确定影响肿瘤学结局的预后因素。
总体而言,54例HG-HV和43例HG-LV腹膜转移患者接受了CRS/HIPEC。HG-HV组手术时间更长,失血量/输血量增加,重症监护病房住院时间延长(p<0.05)。与HG-LV组相比,HG-HV组的宏观不完全细胞减灭(CC-1/2/3)率更高(68.5%对32.6%;p=0.005)。HG-HV疾病患者的生存率低于HG-LV疾病患者(总生存期[OS]分别为17个月和42个月,p=0.009;疾病进展时间[TTP]分别为10个月和14个月,p=0.024)。然而,当实现宏观完全切除(CC-0)时,HG-HV疾病患者的OS和无进展生存期与HG-LV疾病患者相当(OS分别为56个月和52个月,p=0.728;TTP分别为20个月和19个月,p=0.393)。在多变量Cox比例风险回归模型中,CC-0切除是HG-HV疾病患者生存改善的唯一显著预测因素。
尽管与HG-LV疾病患者相比,MAN导致HG-HV腹膜转移的患者预后更差,但当实现宏观完全细胞减灭时,他们的生存率相当。